Disclosure of voting results and Scrutinizers report of the 33rd Annual general meeting held on 29th September, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genpharmasec Ltd held its 33rd AGM on 29 September 2025 via video conferencing (11:04 AM to 11:20 AM). All 7 resolutions were passed with overwhelming majority (over 99.9% in favour on each). Key items approved include: adoption of audited standalone and consolidated financial statements for FY ending March 2025, re-appointment of Mr. Rajesh Sadhwani (retiring by rotation), appointment of M/s Bilimoria Mehta & Co. as Statutory Auditors, appointment of M/s Jaymin Modi & Co. as Secretarial Auditor, revision in remuneration of Whole Time Director & CFO Mr. Sohan Chaturvedi (passed as a Special Resolution), and approval of material related party transactions. Of 107,396 shareholders on record date, 57 attended via VC (2 promoters, 55 public), and about 35.8% of total share votes were polled. Promoters hold 166,001,000 shares (~30% of total 553,719,700 shares) and voted fully in favour on non-conflicted items. For the related party transaction and director re-appointment resolutions, promoter votes were excluded as they were deemed interested.
Routine AGM outcome with full approval of all resolutions, including management remuneration revision and related party transactions — no negative surprises for shareholders. The low public voting turnout (~8.3% of public non-institutional shares) is typical for small-cap companies and means resolutions were largely carried by promoter support.